Submissions for variant NM_033360.4(KRAS):c.351A>C (p.Lys117Asn)

dbSNP: rs770248150

Total submissions: 8

Submitter	RCV	SCV	Clinical significance	Condition	Last evaluated	Review status	Method	Comment
CeGaT Center for Human Genetics Tuebingen	RCV001200581	SCV001371582	pathogenic	not provided	2020-05-01	criteria provided, single submitter	clinical testing
Database of Curated Mutations (DoCM)	RCV000443670	SCV000504420	likely pathogenic	Gastric adenocarcinoma	2016-05-31	no assertion criteria provided	literature only
Database of Curated Mutations (DoCM)	RCV000425583	SCV000504421	pathogenic	Neoplasm of the large intestine	2016-05-31	no assertion criteria provided	literature only
Database of Curated Mutations (DoCM)	RCV000435839	SCV000504422	likely pathogenic	Multiple myeloma	2016-05-31	no assertion criteria provided	literature only
Database of Curated Mutations (DoCM)	RCV000442858	SCV000504423	likely pathogenic	Hepatocellular carcinoma	2016-05-31	no assertion criteria provided	literature only
Database of Curated Mutations (DoCM)	RCV000425803	SCV000504424	likely pathogenic	Carcinoma of esophagus	2016-05-31	no assertion criteria provided	literature only
Database of Curated Mutations (DoCM)	RCV000435219	SCV000504425	likely pathogenic	Malignant melanoma of skin	2016-05-31	no assertion criteria provided	literature only
Genomics For Life	RCV001731671	SCV001981619	pathogenic	Encephalocraniocutaneous lipomatosis		no assertion criteria provided	clinical testing	Whilst the KRAS c.351A>C; p.(Lys117Asn) variant has not previously been reported in oculocutaneous somatic mosaic RASopathies, KRAS pathogenic variants (p.(Ala146Thr), p.(Gly12Asp)) have been reported in these conditions (Chacon-Camacho, Lopez-Moreno et al. 2019). The KRAS c.351A>C; p.(Lys117Asn) (Chr12:g.25378647A>G) variant is equivalent to variant Chr12:g.25378647T>A (Lys117Asn), classified Pathogenic, by ClinVar. The variant is located in a mutational hot spot and/or critical and well-established functional domain without benign variation: UniProt protein RASK_HUMAN nucleotide phosphate binding region 'GTP' has 3 non-VUS missense/in-frame/non-synonymous variants (3 pathogenic and 0 benign), pathogenicity = 100.0% which is more than threshold 50.0%. The variant is found in low frequencies in GnomAD exomes (1/ 251128, allele count = 1 is less than 5 for gene KRAS (good gnomAD exomes coverage = 76.4)) and is not annotated in gnomAD genomes (good gnomAD genomes coverage = 30.4). The variant is a missense variant in a KRAS that has a low rate of benign missense variation and in which missense variants are a common mechanism of disease: 221 out of 225 non-VUS missense variants in gene KRAS are pathogenic = 98.2% which is more than threshold of 51.0%, and 237 out of 418 clinically reported variants in gene KRAS are pathogenic = 56.7% which is more than threshold of 12.0%). In silico analysis of the KRAS c.351A>C; p.(Lys117Asn) variant predicts it to be Deleterious in SIFT (0.0), Damaging in PolyPhen (1.0) and Disease Causing in MutationTaster (Grantham Score: 94.0) with amino acid sequence changed, protein feature possibly affected and is annotated as a known disease mutation (ClinVar ID 375965) (Schwarz, Cooper et al. 2014). Pathogenic computational verdict based on 12 pathogenic predictions from BayesDel_addAF, DANN, DEOGEN2, EIGEN, FATHMM-MKL, LIST-S2, M-CAP, MVP, MutationAssessor, MutationTaster, PrimateAI and SIFT vs no benign predictions (Kopanos, Tsiolkas et al. 2018). ClinVar classifies this variant as Pathogenic, 1 star, associated with a number of different tumour types (https://www.ncbi.nlm.nih.gov/clinvar/variation/375965/). Based on a modification of the ACMG Guidelines (Richards, Aziz et al. 2015, Sukhai, Craddock et al. 2016), the KRAS c.351A>C; p.(Lys117Asn) is classified as a pathogenic variant.